US GAO says FDA failed to address some risks in heparin crisis response
This article was originally published in SRA
Executive Summary
In response to the 2008 heparin crisis, the US Food and Drug Administration increased its activities related to oversight of heparin firms but did not address risks related to working with external entities that had ties to those firms, says a new report by the Government Accountability Office1.